STOCKS TELEGRAPH

Author: Asim Kamal

  • Here is why Qumu Corporation (QUMU) stock faced negativity in the after-hours on Tuesday?

    Here is why Qumu Corporation (QUMU) stock faced negativity in the after-hours on Tuesday?

    Qumu Corporation (QUMU) shares declined 17.14% in after-hours on Tuesday, June 29, 2021, and closed the day at $3.19. Earlier in the morning session, QUMU’s stock gained 3.77% to close Tuesday’s normal trading session at $3.85 per share. QUMU shares have risen 60.42% over the last 12 months, and they have moved up 33.22% in the past week. Over the past three months, the stock has lost 42.88%, while over the past six months, it has plummeted 48.94%.

    Preliminary financial results announcement

    On June 29, 2021, Qumu Corporation released its preliminary financial results for the second quarter ending June 30, 2021.

    Complete financial results for Q2 2021 will be released in late July 2021.

    Preliminary Q2 2021 Financial Highlights

    • For Q2 2021, the company is expecting a total revenue in the range of $5.7 million and $5.9 million compared to revenue of $9.3 million in Q2 2020.
    • For Q2 2021, the gross margin will be in the bracket of 72.5% and 73.5%, compared to 68.5% in Q2 2020.
    • The company is expecting a net loss of $4.9) million to $4.3 million for Q2 2021, compared to et loss of $692,000 in Q2 2020.
    • Adjusted EBITDA loss is expected to be in the range of $5.1 million and $4.8million for Q2 2021, compared to the adjusted EBITDA of $809,000 in Q2 2020.

    Providing video engagement and tracking capabilities to BCFA

    On June 24, 2021, Qumu Corporation announced that it will bring video engagement and tracking capabilities to the Birmingham County Football Association (BCFA).

    This collaboration will provide on-demand BCFA’s video contentto nearly 70,000 football players at 1,200 grassroots football clubs and almost 25,000 volunteers across the West Midlands region.

    Launching of 360-Degree Video on Demand

    On June 15, 2021, Qumu Corporation added 360° video on demand (VOD) to the Qumu Video Engagement Platform. The new addition now gives users the tools to create even richer video content using the 360-degree VOD capability. As a result, organizations can further enhance employee and customer engagement while leveraging Qumu’s trusted security, editing, analytics and storage capabilities.

    New appointment

    On June 2, 2021, Qumu Corporation appointed Susan Young as vice president of strategic alliances and channels. Young will lead Qumu’s strategic partnership program as part of the company’s “better together” strategy, which will be instrumental as the company accelerates momentum in the booming enterprise video market.

    Q1 2021 financial results

    On April 30, 2021, Qumu Corporation announced its financial results for the first quarter ended March 31, 2021.

    • QUMU reported revenue of $5.8 million in Q1 2021, compared to $6.2 million for Q1 2020.
    • The gross margin in Q1 2021 was 73.1% compared to 66.5% for Q1 2020.
    • The company suffered a net loss of $4.5 million, or $0.27 loss per basic share and $0.29 loss per diluted share in Q1 2021 compared to $2.7 million, or $0.20 loss per basic share and $0.21 loss per diluted share, for Q1 2020.
    • In Q1 2021Adjusted EBITDA loss was $4.1 million compared to an adjusted EBITDA loss of $1.2 million for Q1 2020.

    Conclusion

    The preliminary Q2 2021 financial results announcement was the reason behind QUMU loss in the after-hours on Tuesday. The QUMU stock can further dip in the coming days.

  • Here is why MingZhu Logistics Holdings Limited (YGMZ) stock popup in the after-hours on Tuesday?

    Here is why MingZhu Logistics Holdings Limited (YGMZ) stock popup in the after-hours on Tuesday?

    MingZhu Logistics Holdings Limited (YGMZ) shares gained 14.74% in after-hours on Tuesday, June 29, 2021, and closed the day at $5.06 per share. Earlier in the morning session, YGMZ’s stock lost 1.78% to close Tuesday’s normal trading session at $4.41. YGMZ shares have moved up by 1.85% in the past week. Over the past three months, the stock has lost 5.97%, while over the past six months, it has shed 57.18%.

    Let’s see what are the latest news and developments about YGMZ?

    Regaining Nasdaq compliance

    On June 29, 2021, MingZhu Logistics Holdings Limited received notification from The Nasdaq Stock Market LLC confirming the Company has regained compliance with the periodic filing requirement for NASDAQ under Listing Rule 5250(c)(1). NASDAQ noted this matter is now closed.

    Recent financial results announcement

    On June 28, 2021, MingZhu Logistics Holdings Limited released its audited financial results for the full year ended December 31, 2020.

    FY 2020 financial highlights

    • MingZhu Logistics reported revenue of $18.8 million for the year ended December 31, 2020, compared to $29.4 million for the year ended December 31, 2019.
    • Total costs and expenses were $17.4 million for FY 2020 compared to $26.7 million for the year 2019.
    • The company’s comprehensive income was $1.5 million and net income of $0.08 per basic and diluted share in FY 2020 compared to $1.5 million and net income of $0.18 per basic and diluted share for the year 2019.
    • As of December 31, 2020, the company had an $11.6 million balance of cash and restricted cash with a $5.3 million accounts receivable balance and an $11.4 million other receivables balance.

    Closing of Registered Direct Offering

    On March 12, 2021, MingZhu Logistics Holdings closed a registered direct offering of an aggregate of 3,333,335 units of its securities with each Unit consisting of (i) one ordinary share of the Company, par value $0.001 per share, and (ii) one warrant to purchase 0.75 ordinary shares at $6.00 per unit for aggregate gross proceeds of $20 million.

    The company will get net proceeds of approximately $18 million and intends to use the net proceeds for working capital and general corporate purposes.

    MingZhu Logistics agreement with Huawei Logistics

    On March 3, 2021, MingZhu Logistics Holdings announced a significant new strategic cooperation with Guangdong Huawei Modern Logistics Co., Ltd. The cooperation agreement will leverage MingZhu’s trucking fleets and logistics expertise to provide a crucial, integrated link to and from Huawei Logistics’ CHINARAILWAYExpress operation.

    Conclusion

    The YGMZ stock turnaround on Tuesday, after the company, regained Nasdaq compliance and it recently announced its financial results. The YGMZ can continue its positivity in the coming days as well.

  • Here is why Vertex Energy Inc. (VTNR) stock rallied on Tuesday?

    Here is why Vertex Energy Inc. (VTNR) stock rallied on Tuesday?

    Vertex Energy Inc. (VTNR) shares surged 40.99% in after-hours on Tuesday, June 29, 2021, and closed the day at $14.48 per share. Earlier, in the morning session of Tuesday, VTNR’s stock gained 3.32% to close the session at $10.27 per share. VTNR shares have risen 1451.36% over the last 12 months, and they have moved up 39.73% in the past week. Over the past three months, the stock has gained 690.00%. The company has a current market of $479.61 million and its outstanding shares stood at 47.71 million.

    Let’s have a look at its recent news and developments.

    Agreement with Safety-Kleen Systems

    On June 29, 2021, Vertex Energy, Inc entered into a definitive agreement to sell its portfolio of used motor oil collection and recycling assets to Safety-Kleen Systems, Inc.

    Safety-Kleen will acquire the 69 million gallons per year Marrero used oil refinery in Louisiana; the 20 million gallons per year Heartland used oil refinery in Ohio; the H&H and Heartland used oil collections business; the Nickco oil filters and absorbent materials recycling facility in East Texas; and the Cedar Marine terminal in Baytown, Texas.

    The total value of the deal is $140 million and is expected to close during the third quarter of 2021.

    Inauguration on Russell Microcap(R) Index

    Vertex Energy, Inc is set to join the Russell Microcap® Index after the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.

    Acquisition of Alabama Refinery

    On May 26, 2021, Vertex Energy, Inc entered into a definitive agreement to acquire the Mobile refinery for $75 million, located in Mobile, Alabama from Equilon Enterprises LLC d/b/a Shell Oil Products US, Shell Oil Company and Shell Chemical LP (“Shell”), subsidiaries of Royal Dutch Shell plc.

    New appointment

    On May 18, 2021, Vertex Energy, Inc appointed Bart Rice as Division President of Renewable and Conventional Fuels for Vertex.

    Rice has 40 years of energy industry experience and he joined Vertex in early 2000. Before joining Vertex, Rice served in executive leadership roles with Rice Oil, Allied Energy Company, Crystal Energy LLC, Division President of Emerge Energy Services LP and Joint Venture Partner with Lansing Trade Group and Andersons, Inc.

    Financial results announcement

    On May 13, 2021, Vertex Energy, Inc reported its financial results for the first quarter of 2021 ended March 31, 2021.

    Q1 2021 financial highlights

    • Vertex Energy reported anet income of $3.0 million in Q1 2021 compared to $2.4 million in Q1 2020.
    • In Q1 2021, the company earned a revenue of $58.0 million compared to $36.2 million in Q1 2020.
    • Total operating expenses were $8.4 million in the first quarter of 2021 compared to $7.16 million in Q1 2020.
    • Net income attributable to Vertex Energy was $1.0 million compared to $2.8 million in Q1 2020.
    • Income (loss) per share was $0.01 per basic and diluted share in Q1 2021 compared to $0.21 per basic and diluted share in Q1 2020.
    • Adjusted EBITDA was$6.5 million in Q1 2021 compared to $1.65 million in Q1 2020.
    • The company had total cash and availability on its lending facility of $12.5 million and $3.9 million on March 31, 2021.

    Conclusion

    The VTNR stock soared significantly on Tuesday after the company signed agreement to sell its used oil to Safety-Kleen which will generate more revenue for the company. The VTNR stock can further surge in the coming days.

  • Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Altimmune Inc. (ALT) shares plummeted 38.18% in after-hours on Tuesday, June 29, 2021, and closed at $9.83 per share. Earlier in the morning session, ALT’s stock lost 2.45% to close Tuesday’s session at $15.90. ALT shares have risen 52.59% over the last 12 months, and they have moved up 2.19% in the past week. Over the past three months, the stock has gained 17.34%, while over the past six months, it has lost 43.24%.

    The disappointing outcome of AdCOVID™ Phase 1 Clinical Trial

    On June 29, 2021, Altimmune, Inc provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

    80 healthy adult volunteers between the ages of 18 and 55 took part in Phase 1 AdCOVID clinical trial. The volunteers received either 1 or 2 doses of AdCOVID as a nasal spray at 3 dose levels.

    The data showed lower than expected immune responses for each of the immune parameters tested. The magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use.

    Due to poor trial 1 results, Altimmune is discontinuing further development of AdCOVID beyond the completion of this Phase 1 trial.

    Positive Interim Data from ALT-801 Phase 1 Trial

    On June 16, 2021, Altimmune, Inc announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.

    The results showed that a mean weight loss of 5.4% was achieved by Week 6 with a once-weekly ALT-801 dose of 1.8 mg compared to a weight gain of 0.9% in the placebo group.

    Recent financial results

    On May 17, 2021, Altimmune, Inc released its financial results for the three months ending March 31, 2021.

    Q1 2021 financial highlights

    • Altimmune reported revenue of $0.8 million for Q1 2021 compared to $2.2 million inQ1 2020.
    • The company spent $11.9 million in research and development expenses in Q1 2021 compared to $7.2 million in Q1 2020.
    • General and administrative expenses were $3.8 million in Q1 2021 compared to $2.3 million in Q1 2020.
    • The company suffered a net loss of $14.9 million, or $0.38 net loss per share in Q1 2021, compared to $3.9 million, or $0.26 net loss per share in Q1 2020.
    • As of March 31, 2021, Altimmune had cash, cash equivalents, and short-term investments totalling $226.5 million compared to $216.0 million on December 31, 2020.

    Conclusion

    The poor trial one results of the Covid-19 vaccine candidate took the ALT stock to rock bottom. The plummeting can continue on Wednesday as well.

  • Here is why Sensei Biotherapeutics Inc. (SNSE) stock plummeted on Monday?

    Here is why Sensei Biotherapeutics Inc. (SNSE) stock plummeted on Monday?

    Sensei Biotherapeutics Inc. (SNSE) shares declined 8.13% in after-hours on Monday, June 28, 2021, and closed the day at $9.95 per share. Earlier in the morning session, SNSE’s stock lost 1.10% to close Monday’s session at $10.83. SNSE shares have moved down 2.70% in the past week. Over the past three months, the stock has lost 10.05%. The company has a current market of $339.41 million and its outstanding shares stood at 18.91 million.

    Reprioritization of pipeline programs

    On June 28, 2021, Sensei Biotherapeutics reprioritized its pipeline programs to focus on its product candidates, including its multi-antigenic next-generation ImmunoPhage candidate, now referred to as SNS-401-NG, and its monoclonal antibody SNS-VISTA (V-set Immunoglobulin Domain Suppressor of T cell Activation) candidate.

    New Clinical Data from the Combination Trial of SNS-301

    OnMay 19, 2021, Sensei Biotherapeutics reported new data from the ongoing Phase 1/2 clinical trial of SNS-301. The data was priested by Alain Algazi, M.D., from the University of California San Francisco to the medical community at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting which took place virtually from June 4 – 8, 2021.

    SNS-301 is the company’s investigational medicine in patients with advanced squamous cell carcinoma of the head and neck (SCCHN), in combination with pembrolizumab.

    Total 21 patients with locally advanced unresectable or metastatic SCCHN had been enrolled and treated in the study. Twenty of the patients enrolled did not achieve an objective response to prior treatment with PD-1 blockade (Cohort A) and one patient was PD-1 blockade naïve (Cohort B). The safety profile of SNS-301 in combination with pembrolizumab observed from 20 evaluable patients was favourable and consistent with previously reported data.

    Recent financial results announcement

    On May 12, 2021, Sensei Biotherapeutics, Inc announced its financial results for the first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • Research and development expenses were $3.4 million for Q1 2021 compared to $2.2 million for Q1 2020.
    • The company spent $4.6 million in general and administrative expenses in Q1 2021 compared to $1.9 million in Q1 2020.
    • Sensei Biotherapeutics suffered a net loss of $8.0 million for Q1 2021 compared to $4.7 million for the quarter ended March 31, 2020.
    • Net loss per share, basic and diluted was $0.42 per share in Q1 2021 compared to $4.00 in Q1 2020.
    • As of March 31, 2021, the company had cash and cash equivalents of $169.4 million compared to 16.6 million as of December 31, 2020.

    Conclusion

    The company announced its reprioritization of pipeline programs which resulted in a loss on Monday and SNSE price can further go down in the coming days.

  • Why Exela Technologies Inc. (XELA) stock rallied on Monday?

    Why Exela Technologies Inc. (XELA) stock rallied on Monday?

    Exela Technologies Inc. (XELA) shares surged 21.09% in after-hours on Monday, June 28, 2021, and closed the day at $1.78 per share. Earlier in the morning session, XELA’s stock gained 5.76% to close Monday’s normal trading session at $1.47 per share. XELA shares have fallen 8.79% over the last 12 months, and they have moved up 8.89% in the past week. Over the past three months, the stock has lost 31.94%, while over the past six months, it has declined 10.68%.

    Let’s have a look at its recent developments.

    Exela received huge relief from the court

    On June 25, 2021, Exela Technologies, Inc announced that U.S. District Judge Sydney A. Fitzwater has granted Exela’s motion to dismiss in its entirety the Texas federal securities class action suit filed March 2020.

    Participation at the recent investor conference

    Exela Technologies recently participated in the fireside chat hosted by Cantor Fitzgerald’s Josh Siegler that took place on June 11, 2021. The company was presented by Chief Financial Officer Shrikant Sortur and Head of Strategy Matt Brown.

    Expansion of PCH Global Deployment

    On June 08, 2021, Exela Technologies, Inc announced the extension and expansion of its partnership with one of the largest specialty care services insurance carriers in the country.

    This engagement will expand Exela’s powerful cloud-based digital exchange platform for the insurance industry, PCH Global, to approximately 3,800 specialists as registered users within the customer organization using Exela’s proprietary workflow and rule engines across all aspects of the health claims spectrum including behavioural health.

    Recent financial results announcement

    On May 4, 2021, Exela Technologies announced its financial results for the first quarter of its financial year which ended on March 31, 2021.

    Q1 2021 financial highlights

    • Exela Technologies reported revenue of $300.1 million for Q1 2021 compared to $365.5 million for Q1 2020.
    • The company had an operating income of $4.3 million in Q1 2021, compared with an operating loss of $2.2 million in Q1 2020.
    • The company suffered a net loss of $39.2 million in Q1 2021, compared with a net loss of $12.7 million in Q1 2020.
    • Adjusted EBITDA was $46.5 million in Q1 2021 compared to $44.4 million in Q1 2020.

    The financial outlook for FY 2021

    The company is expecting

    • Revenues to be in the range of $1.25 billion to $1.39 billion
    • Gross margin in the range of 23% to 25%
    • Adjusted EBITDA in the range of 16% to 17%
    • Capital expenditures in the range of 1% of revenue

    Conclusion

    Well, as of this writing there is no recent news from this week but recent court relief could be linked with its good performance on Monday. XELA stock can further surge in the coming days.

  • Why Enveric Biosciences Inc. (ENVB) performed well on the first day of the week?

    Why Enveric Biosciences Inc. (ENVB) performed well on the first day of the week?

    Enveric Biosciences Inc. (ENVB) shares gained 5.77% in after-hours on Monday, June 28, 2021, and closed the day at $2.75 per share. Earlier in the morning session, ENVB’s stock gained 19.82% to close Monday’s session at $2.60. ENVB shares have fallen 58.33% over the last 12 months, and they have moved up 25.60% in the past week. Over the past three months, the stock has lost 10.65%, while over the past six months, it has plummeted 61.54%.

    Let’s see is there any recent news behind its good performance on Monday?

    9th Emerging Growth Conference

    The 9th Emerging Growth Conference was hosted by EmergingGrowth.com which held on June 9, 2021.

    The Enveric participated in the conference and the chairman and CEO of the company, David Johnson presented the company at the conference.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Participation in the recent investor conferences

    Enveric Biosciences and MagicMed Industries recently participated at Benzinga Capital Conference which held on Friday, June 4, 2021. The President and CEO of MagicMed, Dr. Joseph Tucker presented the company.

    The company also took part in LD Micro Invitational XI conference which held on June 8, 2021, where it was presented by chairman and CEO of the company, David Johnson.

     

    Acquisition of MagicMed Industries

    On May 24, 2021, Enveric Biosciences entered into a definitive agreement to acquire MagicMed Industries Inc.

    According to the agreement, Dr. Joseph Tucker will be appointed Chief Executive Officer of the Company and David Johnson, current Chief Executive Officer and Chairman will be appointed Executive Chairman.

    Recent financial results announcement

    On May 18, 2021, Enveric Biosciences, Inc announced its financial results for the three months ended March 31, 2021.

    Q1 2021 financial highlights

    • Net cash used in operating activities was $3,162,278during Q1 2021.
    • Total operating expenses were $6,764,997for the quarter ending March 31, 2021, compared to $836,702 for Q1 2020.
    • In Q1 2021 financial activities provided total net cash of $24,881,733.
    • Enveric Biosciences suffered a net loss of $3,250,711 in Q1 2021 compared to $ 1,098,461 in Q1 2020.
    • Net loss per share basic and diluted was $0.20 per share in Q1 2021 compared to $0.19 per share in Q1 2020.

    New Scientific Advisory Board member

    On May 12, 2021, Enveric Biosciences appointed Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company’s Scientific Advisory Board.

    Dr Asher holds a physical medicine and rehabilitation residency at the UCLA / West Los Angeles Veterans Affairs program, as well as a cancer rehabilitation fellowship at the MD Anderson Cancer Center. He is board-certified by the American Board of Physical Medicine and Rehabilitation and Hospice and Palliative Medicine.

    Conclusion

    Well, as of this writing, there is no recent news or development behind its good performance on Monday. We hope that ENVB will continue to outperform other companies in the coming days.

  • Here is why BTRS Holdings Inc. (BTRS) lost its positive momentum on Monday’s after hours?

    Here is why BTRS Holdings Inc. (BTRS) lost its positive momentum on Monday’s after hours?

    BTRS Holdings Inc. (BTRS) shares lost 4.44% in after-hours on Monday, June 28, 2021, and closed the day at $13.13 per share. Earlier in the morning session, BTRS’s stock gained 5.69% to close Monday’s morning session at $13.74 per share. BTRS shares have risen 35.77% over the last 12 months, and they have moved down 6.02% in the past week. Over the past three months, the stock has lost 2.48%, while over the past six months, it has declined 17.23%.

    Public Offering of Common Stock

    On June 28, 2021, BTRS Holdings Inc commenced an underwritten secondary offering of 9,000,000 shares of the Company’s Class 1 common stock.BTRS will not receive any of the proceeds from the offering as all Class 1 common stock is being offered by existing shareholders. Underwrites can buy 1,350,000 additional shares from the existing shareholders of the Company’s Class 1 common stock on the same terms and conditions.

    Debut at U.S Small-Cap Russell 2000® Index

    On June 24, 2021, BTRS Holdings Inc announced that the Company will be added as a member of the Russell 2000® Index effective after the US market opens on June 28, 2021, as part of the Russell US index 2021 annual reconstitution.

    The Russell 2000® Index measures the performance of the small-cap segment of the US equity universe and is a subset of the Russell 3000® Index. Billtrust will also be automatically added to the appropriate growth and value indexes.

    Billtrust Summit 2021

    Billtrust Summit Awards Ceremony was held on May 20, 2021, in which KONE Inc., Gregory Poole Equipment and Global Industrial were recognized as Billtrust Rockstars of the Year, and Commerce Bank as Partner of the Year. ASICS, Design Air, Papé and H&E Equipment Service were also honoured.

    New Business Payments Network 4.0

    On May 18, 2021, Billtrust released the next major version of its Business Payments Network 4.0 (BPN) during its Billtrust Summit 2021 event. BPN 4.0 now supports the bi-directional exchange of transactional data and documents, enabling invoice presentment to accounts payable portals in addition to its existing payment and remittance acceptance capabilities.

    Recent financial results announcement

    On May 12, 2021, BTRS Holdings Inc released its financial results for its first quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • BTRS Holdings earned a total revenue of $41.9 million in Q1 2021 compared to $34.1 million in Q1 2020.
    • In Q1 2021 gross profit was $23.9 million compared to $16.6 million for the same period in 2020.
    • The company suffered a net loss of $22.8 million in Q1 2021, compared to $7.1 million in Q1 2020.

    The financial outlook for FY 2021

    For FY 2021, Billtrustis expecting

    • Total revenue to be in the range of $160 million to $166 million.
    • Net revenue to be between $123 million to $129 million.
    • Adjusted gross profit in the range of $85 million to $89 million.
    • Adjusted EBITDA in the rage of loss of $14million to a loss of $16 million.

    Conclusion

    The public offering of common stock could be the reason behind its loss in the after-hours on Monday but it can also be the reason for its gains as well. Still, it’s not clear why BTRS lost its positivity on Monday evening.

  • Why AC Immune SA (ACIU) stock had a BAD Friday?

    AC Immune SA (ACIU) shares plunged 5.26% in after-hours on Friday, June 25, 2021, and closed the week at $7.75 per share. Earlier, in the morning session, ACIU’s stock lost 2.27% to close Friday’s session at $8.18 per share. ACIU shares have risen 20.12% over the last 12 months, and they have moved up 3.15% in the past week. Over the past three months, the stock has gained 7.21%, while over the past six months, it has declined 48.73%.

    Let’s see what’s happening recently with ACIU?

    Annual General Meeting

    On June 25, 2021, AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.

    Douglas Williams, Martin Velasco, Peter Bollmann, Alan Colowick, Tom Graney, Carl June, Werner Lanthaler, Andrea Pfeifer, and Roy Twyman were re-elected on the Board of Directors by the shareholders. Douglas Williams and Martin Velasco will continue to serve as Chairman and Vice-Chairman of the Board, respectively.

    Update on Alzheimer’s disease Vaccine candidates 

    On June 02, 2021, AC Immune SA provided key clinical and preclinical updates for its SupraAntigen®-derived liposomal vaccine candidates, which are designed to convey active, long-lasting immunization against pathological forms of amyloid-beta (Abeta).

    AC Immune is completing a Phase 2 study of its first clinical candidate, ACI-24, in people with mild Alzheimer’s disease (AD), and is also advancing an optimized ACI-24 formulation, which demonstrates enhanced and sustained immunogenicity in non-human primate studies, particularly against key pathological forms of Abeta such as oligomeric and pyroglutamate Abeta.

    Phase 1b/2a clinical trial expansion of anti-phosphorylated-Tau (pTau) vaccine candidate

    On May 17, 2021, AC Immune SA and its strategic partner Janssen Pharmaceuticals, Inc. expanded the ongoing Phase 1b/2a clinical trial of the Companies’ first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD).

    Recent financial results

    On April 28, 2021, AC Immune SA announced its financial results for the quarter ended March 31, 2021.

    Q1 2021 financial highlights

    • There was no contract revenue for Q1 2021 compared to CHF 12.3 million in Q1 2020.
    • The company spent CHF 13.3 million in R&D expenses compared to CHF 2 million for Q1 2020.
    • General and administrative expenses were CHF 4.3 million for Q1 2021 compared to CHF 4.5 million for Q1 2020.
    • Net loss for the reported quarter was CHF 16.7 million compared with a net loss of CHF 7.7 million for the comparable period in 2020.
    • As of March 31, 2021, the company had a total cash balance of CHF 216.1 million, composed of CHF 151.1 million in cash and cash equivalents and CHF 65 million in short-term financial assets.

    Conclusion

    As of this writing, there was no news or development which could be linked with its poor performance on Friday. so we are unable to predict how ACIU stock will perform in the coming days.

  • Why Alithya Group Inc. (ALYA) stock plummeted on Friday?

    Alithya Group Inc. (ALYA) shares slid down 7.41% in after-hours on Friday, June 25, 2021, and closed the week at $2.50 per share. Earlier in the morning session on Friday, ALYA’s stock lost 0.37% to close Friday’s session at $2.71. ALYA shares have risen 66.26% over the last 12 months, and they have moved down 1.45% in the past week. Over the past three months, the stock has gained 4.23%, while over the past six months, it has declined 24.88%.

    Participation at the upcoming ODTUG Kscope21 Virtual Event

    On June 21, 2021, Alithya Group inc announced that it will participate in the ODTUG Kscope21 Virtual Event, a global conference focused on education within the Oracle user group community.

    The ODTUG Kscope21 Virtual Event is scheduled for June 1 to July 21, 2021, and will cover a wide variety of Oracle technical content topics and will include sessions with real-world solutions, expert panel discussions, live presentations, Q&A sessions, and much more.

    New BénéClic Application

    On June 14, 2021, Alithya Group Inc. launched BénéClic, which is a new mobile application that improves accessibility and connection between volunteers and sick children at Centre Hospitalier Universitaire (CHU) Sainte-Justine, one of the four most important pediatric centres in North America.

    Alithya was approached by CHU Sainte-Justine for a user-friendly mobile app that would streamline what was previously a lengthy process.

    Recent financial results announcement

    On June 10, 2021, Alithya Group Incdisclosed its financial results for its fourth quarter and fiscal 2021, which ended March 31, 2021.

    Q4 2021 financial highlights

    • Alithya Group reported revenue of $78 million for Q4 2021, compared to C$73.2 million in Q4 2020.
    • For Q4 2020, gross profit was $23.5 million compared to C$20.9 million in Q4 2020.
    • Adjusted EBITDA was C$3.3 million for Q4 2021 compared to C$2 million in Q4 2021.
    • The company suffered a net loss of C$2.5 million (-C$0.04 per share) in Q4 2021, compared to a loss of C$34 million (-C$0.59 per share) in Q4 2020.

    FY2021 financial highlights

    • The company earned a revenue of $287.6 million in FY 2021 compared to $279.0 million for fiscal 2020.
    • The gross profit margin was 28.9% for FY 2021 compared to 29.7% for FY 2020.
    • Adjusted EBITDA was 6 million in FY 2021 compared to $11.8 million in FY 2020.
    • The company suffered a net loss of $17.3 million, or $0.30per share in FY 2021 compared to a net loss of $39.7 million, or $0.70 per share in FY 2020.

    Conclusion

    Well, as of this writing, there is no negative news or development which could justify its loss on Friday. we hope that ALYA stock will start the new week in a positive mode.